Opportunity Overview
The accumulation of protein aggregates is a major hallmark of ALS and FTD, suggesting the compromise of protein clearance pathways in the pathogenesis of these diseases (2). One of the ALS/FTD-linked genes encodes sequestosome 1 (SQSTM1/p62), a multi-domain scaffold protein involved in targeting cargo for degradation via autophagy and the ubiquitin-proteasome system. Additionally, p62 serves as a signalling hub for various cellular signal transduction cascades, thereby regulating multiple cellular functions, including the activation of mTORC1 in nutrient sensing, the regulation of inflammation and apoptosis through activation of the nuclear factor kappa-B and the antioxidant response via activation of Keap1-NF-E2-related factor 2 (Nrf2) pathway (3).
Although less extensively investigated, the presence of p62-positive inclusions is not limited to neurons but also extends to astrocytes in the temporal cortex of patients with ALS/FTD (4,5,6,7), as well as astrocytes from FTD cases (8,9) and glial cells in human tauopathies and synucleopathies (10). Despite some evidence, a detailed characterization of the pathology associated with astrocytic p62 in ALS/FTD is currently missing.
In neurodegenerative diseases like ALS and FTD, astrocytes become reactive as part of a conserved physiological response that ultimately result in the gain of new functions and loss or upregulation of homeostatic ones (11). In ALS and FTD, reactive astrocytes contribute to neuron toxicity through non-cell autonomous effects (12). When we modelled...
Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | MRC |
|---|---|
| Country | United Kingdom |
| Category | Research Development |
| Published | September 30, 2022 |
| Procurement stage | Active solicitation |
| Closed | Closing date not published |
| Status | Closed — no longer accepting responses |
| Official source | View original notice |
| Last verified | October 11, 2026 |
Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.
Browse Similar Open Opportunities in United Kingdom
See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United Kingdom Research Development intelligence report in your inbox
A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.